Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Domestic business expected to continue growing above industry growth, targeting double-digit organic growth, supported by key segments like gynec, cardio, derma, consumer, and diabetes. Emcure Pharmaceuticals delivered a strong Q2 FY26 with 25% PAT growth, reporting highest quarterly profit of INR 251 crores.
From Emcure Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Domestic business expected to continue growing above industry growth, targeting double-digit organic growth, supported by key segments like gynec, cardio, derma, consumer, and diabetes.
- International segment projected to maintain strong growth, with Europe and Canada leading; Amphotericin B to launch across Europe by year-end, boosting sales.
- Rest of the World (RoW) sales expected to grow, driven largely by non-ARV products with a healthy order book and strong pipeline.
- Semaglutide opportunity in India seen as large, with over 250 million obese/overweight population, and potential for significant long-term revenue growth via exclusive partnership with Novo Nordisk.
- Continued focus on in-licensing and M&A for portfolio expansion, ensuring accretive growth and margin improvement.
2 more points from Emcure Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Emcure plans ongoing investment in in-house manufacturing capabilities, including complex injectables and biosimilars, which will support product launches globally and contribute to margin expansion over the next 3 to 4 years (Page 7).
- The company expects to deploy generated cash towards M&A opportunities, focusing on expanding in the domestic market by acquiring portfolios for new segments or complementing existing strengths. Bolt-on acquisitions in key international markets like Canada and the UK are also targeted (Page 8).
- Continued investments in R&D to build their own portfolio alongside in-licensing deals, aiming to develop best-in-class products in biologics and chemistry (Page 10).
2 more points from Emcure Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Emcure Pharmaceuticals has a healthy and strong order book currently.
- There is good visibility on orders for the current fiscal year and the next year.
- The recent South African tender went in Emcure's favor, securing orders for both the current year and next year.
2 more points from Emcure Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.5K Cr, net profit ₹244 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Emcure Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
Emcure Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Emcure Pharmaceuticals Ltd Q2 FY26 results?
Domestic business expected to continue growing above industry growth, targeting double-digit organic growth, supported by key segments like gynec, cardio, derma, consumer, and diabetes. Emcure Pharmaceuticals delivered a strong Q2 FY26 with 25% PAT growth, reporting highest quarterly profit of INR 251 crores.
What is Emcure Pharmaceuticals Ltd share price analysis?
Emcure Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 33.5 with a market cap of ₹34,539 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharmaceuticals Ltd planning capital expenditure?
Emcure plans ongoing investment in in-house manufacturing capabilities, including complex injectables and biosimilars, which will support product launches globally and contribute to margin expansion over the next 3 to 4 years (Page 7). - The company expects to deploy generated cash towards M&A opportunities, focusing on expanding in the domestic market by acquiring portfolios for new segments or complementing existing strengths.
Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.